#China #Shanghai #Fosun Pharma #RZL-012 #Raziel Therapeutics

Raziel Therapeutics and Fosun Pharma Celebrate Phase 3 Trial Success for RZL-012

Raziel Therapeutics, an innovative pharmaceutical company focused on advancing prescription products in the aesthetics realm, has recently announced significant progress regarding their product RZL-012. This injectable lipolytic drug targets the reduction of submental fat, commonly referred to as a double chin. The results from their Phase 3 clinical trial, conducted in collaboration with Fosun Pharma, introduced promising data that could reshape approaches to fat reduction treatments in China.

The Breakthrough Findings

In a pivotal clinical study involving 480 participants, of which 360 received the active treatment and 120 received a placebo, RZL-012 succeeded in meeting all primary and secondary endpoints concerning efficacy and safety. In particular, the treatment demonstrated a notable 30 percentage-point advantage over the placebo group concerning responder rates. These results are set to expedite the submission of a New Drug Application (NDA) to Chinese regulatory authorities by the end of 2026. The trial evaluated the drug's effectiveness 84 days post-treatment, showcasing its potential in delivering noticeable aesthetic improvements through minimal intervention.

Expanding the Scope of Application

This Phase 3 trial represents just the beginning of RZL-012’s journey in the medical aesthetics field, as both Raziel and Fosun are already planning post-trial steps. With Fosun preparing additional clinical trials focusing on body contouring, it indicates their confidence in the product’s versatility and ability to penetrate the broader market of focal fat reduction. RZL-012’s development comes at a crucial time, where the demand for effective fat reduction treatments is increasing, particularly in tandem with rising systemic weight-loss therapies.

Insights from Leadership

Alon Bloomenfeld, Founder and CEO of Raziel Therapeutics, expressed his enthusiasm regarding the results, stating, "We are thrilled with the success of RZL-012 in this Phase 3 trial in China. This data demonstrates the superiority of RZL-012 in the focal fat reduction market. We believe RZL-012 will become the gold standard treatment for fat reduction across aesthetic indications."
Conversely, Phillip Cui, Co-CEO of Fosun Health Capital, aligned with these sentiments, emphasizing their shared values rooted in innovation and care for life. These sentiments reinforce the importance of collaborative efforts as they strive to meet unmet needs within the aesthetics sector.

Mechanism of Action and Administration

RZL-012 operates via a unique mechanism that involves the targeted destruction of fat cells when injected under the skin. Administered by trained professionals, the drug's injections require just one to two sessions, making it a viable option for patients seeking effective cosmetic enhancements without extensive downtime. Once the fat cells are destroyed, they cannot store or accumulate fat, thereby promoting a leaner appearance in the treated area.

About the Companies

Fosun Health Capital stands as the venture capital arm of Fosun Pharma, known for its early-stage investments in promising medical innovations that exhibit strong growth potential. Since 2019, it has supported various companies across different modalities, expanding its clinical pipeline in sectors like oncology and aesthetic treatments.
Meanwhile, Raziel Therapeutics is carving its niche as a forward-thinking pharmaceutical company originating from Israel, specializing in innovative treatments for aesthetic applications. Their lead compound RZL-012 is set to shape industry standards as it moves through regulatory processes.

Conclusion

With the promising results from the Phase 3 trial, Raziel Therapeutics and Fosun Pharma position themselves as influential players in the medical aesthetics landscape in China. As they prepare to submit their NDA, the industry's eyes will be keenly focused on RZL-012, which potentially paves the way for new standards in aesthetic treatments aimed at fat reduction.